ALK signaling and target therapy in anaplastic large cell lymphoma

ALK signaling and target therapy in anaplastic large cell lymphoma

Blog Article

The discovery by Morris SW et al.in 1994 of the genes contributing to the t(2;5)(p23;q35) translocation has put the foundation for a molecular based recognition of Anaplastic Large Cell Lymphoma (ALCL) and pointed out the need for a further stratification of T-cell Resistor neoplasia.Likewise the detection of ALK genetic lesions among many human cancers has defined unique subsets of cancer patients, providing new opportunities for innovative therapeutic interventions.The objective of this review is to appraise the molecular drive set mechanisms driving ALK-mediated transformation, and to maintain the neoplastic phenotype.

The understanding of these events will allow the design and implementation of novel tailored strategies for a well-defined subset of cancer patients.